IDEXX Laboratories (NASDAQ:IDXX) Updates FY 2025 Earnings Guidance

Key Points

• IDEXX Laboratories has updated its FY 2025 earnings guidance, expecting earnings per share to be between $12.400 and $12.760, surpassing the consensus estimate of $12.162.
• The company's revenue guidance is set at $4.2 billion to $4.3 billion, higher than the consensus estimate of $4.1 billion.
• IDEXX shares opened at $535.54, with a market cap of $43.07 billion, and are currently rated as a "Moderate Buy" by analysts.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided earnings per share guidance of 12.400-12.760 for the period, compared to the consensus earnings per share estimate of 12.162. The company issued revenue guidance of $4.2 billion-$4.3 billion, compared to the consensus revenue estimate of $4.1 billion.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $535.54 on Monday. The company has a market cap of $43.07 billion, a price-to-earnings ratio of 49.50, a PEG ratio of 3.81 and a beta of 1.49. The business has a 50 day moving average price of $531.30 and a 200 day moving average price of $472.10. The company has a quick ratio of 0.81, a current ratio of 1.16 and a debt-to-equity ratio of 0.31. IDEXX Laboratories has a twelve month low of $356.14 and a twelve month high of $579.47.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. Research analysts predict that IDEXX Laboratories will post 11.93 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on IDXX shares. Morgan Stanley lifted their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Leerink Partners upped their target price on IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Jefferies Financial Group began coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price target on the stock. Wall Street Zen upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Saturday, July 12th. Finally, Stifel Nicolaus lifted their target price on shares of IDEXX Laboratories from $510.00 to $540.00 and gave the company a "hold" rating in a research report on Wednesday, July 2nd. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $557.88.

Insider Buying and Selling

In other news, Director M Anne Szostak sold 1,260 shares of the firm's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the sale, the director owned 1,801 shares of the company's stock, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.98% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On IDEXX Laboratories

A hedge fund recently raised its stake in IDEXX Laboratories stock. Empowered Funds LLC lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 6.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,538 shares of the company's stock after buying an additional 95 shares during the quarter. Empowered Funds LLC's holdings in IDEXX Laboratories were worth $646,000 at the end of the most recent quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.